Immediate Impact

1 from Science/Nature 54 standout
Sub-graph 1 of 22

Citing Papers

Why do patients with cancer die?
2024 Standout
Global Epidemiology and Genetics of Hepatocellular Carcinoma
2023 Standout
2 intermediate papers

Works of P. Foa being referenced

Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment.
2011
Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer
2009

Author Peers

Author Last Decade Papers Cites
P. Foa 136 240 180 148 26 501
T. Girinsky 90 248 182 99 22 569
Romeo A. Mandanas 102 92 166 225 21 456
Camilla Molich Hoff 95 164 137 141 20 571
Loredana Costa 200 172 63 123 29 489
In Keun Choi 82 131 95 82 36 417
Richard Lizambri 310 177 159 49 16 506
Umut Dişel 78 145 107 47 46 459
Jan‐Erik Johansson 118 117 170 32 29 443
Francesco Grimaldi 69 120 161 66 29 449
J M Cosset 88 217 313 54 32 540

All Works

Loading papers...

Rankless by CCL
2026